Growth Metrics

Trevi Therapeutics (TRVI) Cash from Financing Activities (2018 - 2026)

Trevi Therapeutics' quarterly Cash from Financing Activities came in at $222000.0 in Q1 2026, down 97.45% year-on-year from $8.7 million in Q1 2025, and down 21.83% quarter-over-quarter from $284000.0 in Q4 2025.

Trevi Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $222000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 97.45% year-over-year to $222000.0; the trailing twelve-month figure through Mar 2026 stood at $112.5 million (up 60.26% YoY), and the FY2025 full-year result was $121.0 million, up 96.82% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $222000.0, down from $284000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $110.4 million in Q2 2025, with the low at -$7.7 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $16.8 million, with a median of $1.5 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities tumbled 172.48% in 2023 and jumped 95409.26% in 2024.
  • Tracing TRVI's Cash from Financing Activities over 5 years: stood at $652000.0 in 2022, then plunged by 108.28% to -$54000.0 in 2023, then jumped by 95409.26% to $51.5 million in 2024, then sank by 99.45% to $284000.0 in 2025, then slipped by 21.83% to $222000.0 in 2026.
  • The last three Cash from Financing Activities figures came in at $222000.0 (Q1 2026), $284000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Trevi Therapeutics 2.02 Bn 1.85 Bn - 222,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 222,000.00
Mar 31, 2026 222,000.00
Dec 31, 2025 284,000.00
Dec 31, 2025 284,000.00
Sep 30, 2025 1.63 Mn
Sep 30, 2025 1.63 Mn
Jun 30, 2025 110.40 Mn
Jun 30, 2025 110.40 Mn
Mar 31, 2025 8.71 Mn
Mar 31, 2025 8.71 Mn
Dec 31, 2024 51.47 Mn
Dec 31, 2024 51.47 Mn
Sep 30, 2024 4.98 Mn
Sep 30, 2024 4.98 Mn
Jun 30, 2024 5.07 Mn
Jun 30, 2024 5.07 Mn
Mar 31, 2024 -28,000.00
Mar 31, 2024 -28,000.00
Dec 31, 2023 -54,000.00
Dec 31, 2023 -54,000.00
Sep 30, 2023 1.51 Mn
Sep 30, 2023 1.51 Mn
Jun 30, 2023 -7.66 Mn
Jun 30, 2023 -7.66 Mn
Mar 31, 2023 -1.70 Mn
Mar 31, 2023 -1.70 Mn
Dec 31, 2022 652,000.00
Dec 31, 2022 652,000.00
Sep 30, 2022 55.30 Mn
Sep 30, 2022 55.30 Mn
Jun 30, 2022 55.98 Mn
Jun 30, 2022 55.98 Mn
Mar 31, 2022 -625,000.00
Mar 31, 2022 -625,000.00
Dec 31, 2021 13.74 Mn
Dec 31, 2021 13.74 Mn
Sep 30, 2021 134,000.00
Sep 30, 2021 134,000.00
Jun 30, 2021 2.75 Mn
Jun 30, 2021 2.75 Mn
Mar 31, 2021 4.15 Mn
Mar 31, 2021 4.15 Mn
Dec 31, 2020 637,000.00
Dec 31, 2020 637,000.00
Sep 30, 2020 16.10 Mn
Sep 30, 2020 16.10 Mn
Sep 30, 2019 -138,000.00
Sep 30, 2019 -138,000.00
Jun 30, 2019 63.50 Mn
Jun 30, 2019 63.50 Mn
Mar 31, 2019 9.85 Mn
Mar 31, 2019 9.85 Mn
Dec 31, 2018 -1.51 Mn
Dec 31, 2018 -1.51 Mn
Sep 30, 2018 10.47 Mn
Sep 30, 2018 10.47 Mn
Jun 30, 2018 -3.28 Mn
Jun 30, 2018 -3.28 Mn
Mar 31, 2018 -2.05 Mn
Mar 31, 2018 -2.05 Mn